| Outcome Measures: |
Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period, The baseline hemoglobin value is defined as the mean of the two most recent hemoglobin values taken prior to the day of randomization plus the value obtained on the day of randomization prior to Dose 1. The mean hemoglobin during the Evaluation period for each participant is calculated as the mean of the available hemoglobin values during Study Weeks 21 through 28., Baseline and Weeks 21-28 | Secondary: Proportion of Participants Who Receive Red Blood Cell (RBC) or Whole Blood Transfusions During the Correction and Evaluation Periods, Weeks 1 to 28|Proportion of Participants Achieving Hemoglobin Response During the Correction and Evaluation Periods, A hemoglobin response is defined as a hemoglobin increase of ≥ 1.0 g/dL above baseline and a hemoglobin ≥ 11.0 g/dL without RBC or whole blood transfusion during the previous 8 weeks., Weeks 1 to 28
|
| Locations: |
Research Facility, Irkutsk, Russian Federation|Research Facility, Krasnodar, Russian Federation|Research Facility, Krasnoyarsk, Russian Federation|Research Facility, Moscow, Russian Federation|Research Facility, Nizhniy Novgorod, Russian Federation|Research Facility, Omsk, Russian Federation|Research Facility, Petrozavodsk, Russian Federation|Research Facility, Saratov, Russian Federation|Research Facility, St. Petersburg, Russian Federation|Research Facility, Tver, Russian Federation|Research Facility, Volzhsk, Russian Federation
|
